

Prognostic Value of Serum AFP in HCC Egyptian Patients

Thesis

Submitted For Partial Fulfillment of Master
Degree

In Tropical Medicine

Presented by

Mostafa Abdelfattah Shamkh Ahmad
M.B., B.Ch.

Under Supervision of

Prof. Dr / Waleed Abdelatty Hamed

*Professor of Tropical Medicine
Faculty of Medicine-Ain Shams University*

Assis. Prof. Dr / Mohammed Omar Khalifa

*Assistant Professor of Tropical Medicine
Faculty of Medicine-Ain Shams University*

Doctor / Ashraf Mohammed El Breedy

*Lecturer of Tropical Medicine
Faculty of Medicine-Ain Shams University*

**Faculty of Medicine
Ain Shams University**

2015

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgement

First and Foremost, I feel thankful to Allah, the most beneficial, the merciful.

I wish to express my deepest gratitude to Prof. Dr.Waleed Abdelaaty Hamed Professor of Tropical Medicine Department, Faculty of Medicine, Ain Shams University, for his guidance, scientific supervision and support. It has been an honour to work under his generous supervision.

Words fail to express my sincere appreciation, great gratitude to Assis.Prof. Dr.Mohammad Omar Khalifa, Assistant Professor of Tropical Medicine Department, Faculty of Medicine, Ain Shams University, whose continuous supervision advice and fruitful criticism have been of great help in performing this work.

I wish to express my thanks and profound gratitude to Dr. Ashraf Mohammad ElBreeady lecturer of Tropical Medicine, Faculty of Medicine, Ain Shams University, for giving me the honour and great advantage of working under his supervision. His valuable teaching and continuing education to me extend far beyond the limits of this thesis.

Last but not least, I would like to thank my Family for their great and kind support.

Mostafa Abdelfattah Shamkh Ahmad

LIST OF CONTENTS

<i>Title</i>	<i>Page</i>
▪ Introduction	1
▪ Aim of the Work	4
▪ Review of the Literature:	
✓ Chapter 1: Hepatocellular Carcinoma (HCC)	5
✓ Chapter 2: Alfa fetoprotein (AFP)	68
▪ Patients and Methods	121
▪ Results	130
▪ Discussion	170
▪ Summary	190
▪ Conclusion	195
▪ Recommendations	196
▪ References	197
▪ Arabic Summary	—

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
<i><u>Figures of Review</u></i>		
Figure (1):	CT imaging of HCC	38
Figure (2):	MRI imaging of HCC	39
Figure (3):	Recent modification in the algorithm for investigation of small nodules found on screening in patients at risk for HCC	43
Figure (4):	Modified Sixth edition TNM classification of HCC (is simplified into 4 stages to represent the optimum prognostic prediction)	47
Figure (5):	Okuda Staging System for HCC	48
Figure (6):	Barcelona Clinic Liver Cancer (BCLC) Classification	50
Figure (7):	Barcelona Clinic Liver Cancer staging classification and treatment schedule	51
Figure (8):	Recent modification in the proposed staging and treatment strategies for patients with HCC according to the BCLC	57
Figure (9):	Summary of treatment modalities for HCC	58
Figure (10):	Key pathways in hepatocarcinogenesis	66
Figure (11):	3-D shape of the AFP molecule	72
Figure (12):	Schematic illustration of the possible role of cytoplasmic AFP in the AKT signal pathway.....	86

Figures of Results

Figure (1): Classification of the patients according to the baseline AFP level into three groups	139
Figure (2): Comparison between the three groups of patients regarding overall survival	147
Figure (3): Comparison between the three groups of patients regarding overall survival rates in patients who underwent RFA.....	149
Figure (4): Comparison between the three groups of patients who underwent RFA regarding disease free survival	151
Figure (5): Comparison between the three groups of patients regarding overall survival rates in patients who underwent TACE	153
Figure (6): Comparison between the three groups of patients who underwent TACE regarding time to progression	155
Figure (7): Prognostic validity of baseline AFP to predict mortality	157
Figure (8): The relation between the degree of decrease of AFP one month after a procedure and overall survival.....	159
Figure (9): The relation between the degree of decrease of AFP one month after RFA and survival time	160
Figure (10): The relation between the degree of decrease of AFP one month after RFA and disease free survival	161

Figure (11): The relation between the degree of decrease of AFP one month after TACE and survival time	162
Figure (12): The relation between the degree of decrease of AFP one month after TACE and time to progression	163
Figure (13): Effect of the degree of decrease of AFP one month after a procedure in group III patients on overall survival.....	164
Figure (14): Comparison between the three groups of patients (according to baseline AFP) regarding overall survival in patients with uninodular HCC (regardless the type of the procedure done).....	165
Figure (15): Comparison between the three groups of patients (according to baseline AFP) regarding time till first recurrence (regardless the type of the procedure done).....	166
Figure (16): Comparison between the three groups of patients (according to baseline AFP) regarding overall survival in patients with multinodular HCC (regardless the type of the procedure done).....	167
Figure (17): Comparison between the three groups of patients (according to baseline AFP) regarding overall survival in patients with lesions ≤ 5 cm (regardless the type of the procedure done)	168

Figure (18): Comparison between the three groups of patients (according to baseline AFP) regarding overall survival in patients with lesions > 5 cm (regardless the type of the procedure done).....169

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
------------------	--------------	-----------------

Tables of Patients and Methods

Table (1):	Overall Response Assessment in mRECIST criteria.....	127
-------------------	--	-----

Tables of Results

Table (1):	Description of patients' demographic data	131
Table (2):	Description of patients' clinical data.....	132
Table (3):	Description of patients' laboratory results	133
Table (4):	Description of results of CT imaging	135
Table (5):	Distribution of patients according to different staging and scoring systems	136
Table (6):	The interventions done for the patients in the study	137
Table (7):	Overall survival rate of all patients without grouping.....	138
Table (8):	Comparison between the three groups of patients regarding demographic data	140
Table (9):	Comparison between the three groups of patients regarding clinical data.....	141
Table (10):	Comparison between the three groups of patients regarding laboratory results	142
Table (11):	Comparison between the three groups of patients regarding the results of CT imaging	143

Table (12): Comparison between groups of patients regarding different staging systems	144
Table (13): Comparison between the three groups of patients regarding mortality rate	145
Table (14): Comparison between the three groups of patients (according to baseline AFP) regarding cumulative survival rate.....	146
Table (15): Comparison between the three groups of patients who underwent RFA regarding type of response after one month (mRECIST)	148
Table (16): Comparison between the three groups of patients who underwent RFA regarding cumulative survival rates.....	150
Table (17): Comparison between three groups of patients who underwent TACE regarding type of response after one month (mRECIST).....	152
Table (18): Comparison between the three groups of patients who underwent TACE regarding cumulative survival rates.....	154
Table (19): Relation of baseline AFP with biochemical results, tumor size and tumor number	156
Table (20): Changes in the level of AFP one month after a procedure	158

List of Abbreviations

Abbreviation	Full term
α F	α feutin
β -catenin	cadherin-associated protein beta 1
μ g	microgram
μ mol	micromole
18F-FDG	Fluorine-18 fluorodeoxyglucose
99m TC	Technetium 99
Å	Angstrom
A. parasiticus	Aspergillus parasiticus
AASLD	American Association for the Study of Liver Diseases
AFB1	Aflatoxin B1
AFB2	Aflatoxin B2
AFG1	Aflatoxin G1
AFG2	Aflatoxin G2
AFP	Alpha-fetoprotein
AFPep	Alpha Fetoprotein Peptide
AFP-L3	Lens culinaris agglutinin reactive Alpha-fetoprotein
AFU	Alpha-l-fucosidase
AKT	Protein kinase B
ALT	Alanine transaminase
AP-1	Activator protein 1

APC	Antigen-presenting cell
ApoAI	Apolipoprotein A-I
A-T	Ataxia Telangiectasia
AT	Alpha-1-antitrypsin
ATM	Ataxia telangiectasia mutated protein
ATRA	All- trans retinoic acid
ATZ	Alpha-1-antitrypsin Z allele
AUC	area under curve
B cell	B lymphocyte
BALAD	Bilirubin, Albumin, AFP-L3, AFP, DCP system
BCL2	B-cell lymphoma 2 : an apoptosis regulator protein
BCLC	Barcelona Clinic Liver Cancer
BCS	Budd-Chiari syndrome
C282Y	Hemochromatosis gene (HFE) C282Y mutation
c-fos	A proto-oncogene
c-jun	A protein that in humans is encoded by the JUN proto oncogene
Ca	Calcium
caspase	Cysteine-dependent aspartate-directed proteases
CBC	Complete blood count
CCC	Cholangiocarcinoma
Cd	Cadmium
CD4	Cluster of differentiation 4
CEUS	Contrast enhanced ultrasound
CI	Confidence interval
CLD	Chronic liver disease

CLIP	Cancer of the Liver Italian Program
CLIP-2	Modified Cancer of the Liver Italian Program
cm	centimeter
Co	Cobalt
Con A	Concanavalin A
CR	Complete response
Creat	Creatinine
CT	Computed tomography
CTL	Cytotoxic T lymphocyte
Cu	Copper
Cum survival	Cumulative survival
CUPI	Chinese University Prognostic Index
d	day
Da	dalton
DAAs	Direct acting antivirals
DC	Dendritic cell
DCP	Des-gamma carboxyprothrombin
DFS	Disease free survival
dl	deciliter
DM	Diabetes mellitus
DMSA	Dimercaptosuccinic acid
DNA	Deoxy ribo nucleic acid
E	Estrogen
EASL	European Association for the Study of the Liver

ECOG	Eastern Cooperative Oncology Group
EGF	Epidermal growth factor
EGFR	Epidermal growth factor receptors
EPI	Expanded Program of Immunization
ER	Endoplasmic reticulum
ESA-globulin	Embryo specific globulin
ESLD	End stage liver disease
EUS	Endoscopic Ultrasound
Fas	FAS receptor: cluster of differentiation (CD) 95
FasL	Fas ligand
FGF	Fibroblast growth factor
FL	Focal lesion
FNAB	Fine needle aspiration biopsy
FSH	Follicular-stimulating hormone
GD-EOB-DTPA	Gadolinium ethoxybenzyl diethylenetriaminepenta-acetic acid
GGT	Gamma-glutamyl transferase
GIP	growth inhibitory peptide
gm	gram
GPC3	Glypican-3
GRETCH	Groupe d'Etude et de Traitement du Carcinoma Hepatocellulaire
GTPase	guanosine triphosphatase
Hb	hemoglobin
HBeAg	Hepatitis B e antigen

HBsAg	Hepatitis B surface antigen
HBV	Hepatitis B virus
HBx	Hepatitis B x gene
HCC	Hepatocellular carcinoma
HCG	Human chorionic gonadotropin
HCV	Hepatitis C virus
HCVAb	Hepatitis C virus antibody
HDGF	Hepatoma-derived growth factor
HDV	Hepatitis D virus
HE	Hepatic encephalopathy
HepG2 cells	Human hepatoma cell line culture
HFE	Hereditary hemochromatosis gene(High Iron Fe)
HFL	hepatic focal lesion
HGF	Hepatocyte growth factor
HH	Hereditary hemochromatosis
HIV	Human immunodeficiency virus
HPAFP	Hereditary persistence of AFP
HS-AFP	Hepatoma specific AFP
HS-GGT	Hepatoma specific gamma-glutamyl transferase
HTN	Hypertension
IGF-I	Insulin-like growth factor- I
IGF-II	Insulin growth factor-II
IL-4	Interleukin-4
IL-6	Interleukin-6
IL-8	Interleukin-8
IL-12	Interleukin-12